Cazzaniga G - Search Results

1

High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia.

Oikonomou A, Valsecchi L, Quadri M, Watrin T, Scharov K, Procopio S, Tu JW, Vogt M, Savino AM, Silvestri D, Valsecchi MG, Biondi A, Borkhardt A, Bhatia S, Cazzaniga G, Fazio G, Bardini M, Palmi C. Oikonomou A, et al. Among authors: cazzaniga g. Biochem Pharmacol. 2023 Nov;217:115809. doi: 10.1016/j.bcp.2023.115809. Epub 2023 Sep 17. Biochem Pharmacol. 2023. PMID: 37717691 Free article.

2

Monitoring minimal residual disease using chromosomal translocations in childhood ALL.

Cazzaniga G, Rossi V, Biondi A. Cazzaniga G, et al. Best Pract Res Clin Haematol. 2002 Mar;15(1):21-35. doi: 10.1053/beha.2002.0183. Best Pract Res Clin Haematol. 2002. PMID: 11987914 Review.

3

Molecular characterization of a new recombination of the SIL/TAL-1 locus in a child with T-cell acute lymphoblastic leukaemia.

Carlotti E, Pettenella F, Amaru R, Slater S, Lister TA, Barbui T, Basso G, Cazzaniga G, Rambaldi A, Biondi A. Carlotti E, et al. Among authors: cazzaniga g. Br J Haematol. 2002 Sep;118(4):1011-8. doi: 10.1046/j.1365-2141.2002.03747.x. Br J Haematol. 2002. PMID: 12199779 Free article.

4

Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response.

Cazzaniga G, Lanciotti M, Rossi V, Di Martino D, Aricò M, Valsecchi MG, Basso G, Masera G, Micalizzi C, Biondi A. Cazzaniga G, et al. Br J Haematol. 2002 Nov;119(2):445-53. doi: 10.1046/j.1365-2141.2002.03838.x. Br J Haematol. 2002. PMID: 12406084 Free article.

5

FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia.

Arrigoni P, Beretta C, Silvestri D, Rossi V, Rizzari C, Valsecchi MG, Cazzaniga G, Biondi A. Arrigoni P, et al. Among authors: cazzaniga g. Br J Haematol. 2003 Jan;120(1):89-92. doi: 10.1046/j.1365-2141.2003.04032.x. Br J Haematol. 2003. PMID: 12492581 Free article.

6

Results of minimal residual disease (MRD) evaluation and MRD-based treatment stratification in childhood ALL.

Cazzaniga G, d'Aniello E, Corral L, Biondi A. Cazzaniga G, et al. Best Pract Res Clin Haematol. 2002 Dec;15(4):623-38. doi: 10.1053/beha.2002.0228. Best Pract Res Clin Haematol. 2002. PMID: 12617867 Review.

7

Minimal residual disease as a surrogate marker for risk assignment to ALL patients.

Cazzaniga G, Gaipa G, Rossi V, Biondi A. Cazzaniga G, et al. Rev Clin Exp Hematol. 2003 Sep;7(3):292-323. Rev Clin Exp Hematol. 2003. PMID: 15024971 Review.

8

Molecular monitoring of childhood acute lymphoblastic leukemia using antigen receptor gene rearrangements and quantitative polymerase chain reaction technology.

Cazzaniga G, Biondi A. Cazzaniga G, et al. Haematologica. 2005 Mar;90(3):382-90. Haematologica. 2005. PMID: 15749670 Review.

9

Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype.

Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B. Cazzaniga G, et al. Blood. 2005 Aug 15;106(4):1419-22. doi: 10.1182/blood-2005-03-0899. Epub 2005 May 3. Blood. 2005. PMID: 15870172 Free article.

10

TEL/ARG induces cytoskeletal abnormalities in 293T cells.

Palmi C, Fazio G, Cassetti A, Aloisi A, Villa A, Biondi A, Cazzaniga G. Palmi C, et al. Among authors: cazzaniga g. Cancer Lett. 2006 Sep 8;241(1):79-86. doi: 10.1016/j.canlet.2005.10.017. Epub 2005 Nov 28. Cancer Lett. 2006. PMID: 16310306

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

347 results

Search Page